Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Biogen Idec Inc. (NASDAQ:BIIB) reported $192.1 million in 2Q13 sales of newly launched multiple sclerosis drug Tecfidera dimethyl fumarate, more than double Street estimates of around $75
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury